Article A Single Blind, Placebo-controlled, Randomised Study in Mild to Moderate Alzheimer's Disease Patients to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK239512, a Selective Histamine H3 Receptor Antagonist

This is a safety and tolerability study to investigate the effect of GSK239512 on mild to moderate Alzheimer's disease patients. The dose of GSK239512 will be titrated to reach the most well tolerated dose in the patients.

For more information on this study, visit the Study Record Detail of the respective clinical trial here.

Manuscripts citing this dataset

  • The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation. 2013. DOI: 2174/1567205011310030003

Request access

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.

Data Use Agreement

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here.

Publishing results using this dataset?

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.


Post a question or thought about this dataset here.